The FDA gave orphan designation to Anthera Pharmaceuticals' blisibimod to treat immunoglobulin A nephropathy, or Berger's disease. Anthera said it could report later this month on a midstage trial of the drug, a B-cell activating factor antagonist.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.